|
HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Communications
|
Committee, Work group, Advisory group, or Task Force
|
ACL, OS
|
NIDA, NIMH
|
A subcommittee of the HHS Behavioral Health Coordinating Committee is a coordinating body within the U.S. Department of Health and Human Services (HHS) that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. This subcommittee of communication professionals collaborates on inter-departmental behavioral health initiatives and promotional efforts.
|
|
HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Prescription Drug Abuse
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
NIDA
|
A subcommittee of the HHS Behavioral Health Coordinating Committee is a coordinating body within the U.S. Department of Health and Human Services (HHS) that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. The National Institute of Drug Abuse (NIDA) Serves as Co-Chair with FDA on this inter-agency subcommittee addressing prescription drug abuse.
|
|
HHS Behavioral Health Coordinating Committee Subcommittee for Communications
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, HRSA, OS, SAMHSA
|
OD/DPCPSI/OBSSR, NIAAA, NIDA
|
The communications subcommittee is developing tools to enhance cross-HHS communications on behavioral health with other federal agencies and the public. Initiatives include platforms for data sharing and dissemination across HHS agencies, and establishing common language for behavioral health
|
|
HHS Biannual Dual Use Research of Concern (DURC) Inventory
|
Resource Development
|
CDC, FDA, OS
|
OD/OSP, CC, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI
|
Development of the HHS Biannual Dual Use Research of Concern (DURC) inventory reports, as required by the USG Policy for Oversight of Dual Use Research of Concern.
|
|
HHS Biomedical Advanced Research and Development Authority (BARDA) Radiological/Nuclear Integrated Program Team
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
This Interagency Working Group, established under the Biomedical Advanced Research and Development Authority (BARDA), determines overall radiation countermeasures strategy and priorities. The National Institute of Allergy and Infectious Diseases (NIAID) provides subject matter expertise, advice and guidance on medical countermeasure development, requirements, and preparedness/response.
|
|
HHS Biotechnology Engagement Program (BTEP)
|
Research Initiative
|
CDC, FDA
|
NIAID, NCI
|
The BTEP supports scientific programs in the Former Soviet Union and the Commonwealth of Independent States to engage former weapons scientists and new investigators in collaborative research areas of common interest related to public health.
|
|
HHS Biovigilance Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC, NHLBI
|
This committee develops systems for reporting adverse events resulting from blood transfusion or donation.
|
|
HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, OS
|
NHLBI, CC
|
The HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is chaired by the Assistant Secretary for Health and voting members are the senior-most heads of the relevant Staff divisions and Operating divisions of HHS (e.g., the Director of CDC and NIH, Administrator of CMS, and Commissioner of FDA). The BOTSEC is an internal council chartered to consider significant issues and make decisions that require cross-Agency input, including resources. In important aspect of the BOTSEC is the formation of HHS-wide (i.e., multi-Agency) working groups to explore significant public health items such as re-examining the lifetime blood donor deferral policy for MSM, and the creation of hemovigilance systems to collect and analyze data on adverse events that occur during the blood donation and utilization processes.
|
|
HHS Climate Adaptation Strategies
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
NIEHS
|
NIEHS has been partnering with the Assistant Secretary for Health (ASH), the Assistant Secretary for Administration (ASA), and more recently the Assistant Secretary for Preparedness and Response (ASPR) and other operating and staff divisions of HHS to respond to White House directives on climate change adaptation at the agency level. This includes production of the HHS Climate Adaptation Plan and the coordination and production of deliverables under the President''s Climate Action Plan.
|
|
HHS Diagnostics Integrated Program Team (DxIPT)
|
Other
|
CDC, FDA
|
NIAID
|
The DxIPT was established by the USG Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Executive Committee. The DxIPT will advise leadership on investments in human health diagnostics, medical countermeasures to improve the response to chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. Members include Federal employees or contractors to the Federal Government with diverse expertise in diagnostics. In 2012, DxIPT was charged with two tasks: 1) to reevaluate the feasibility of anthrax diagnostics for asymptomatic infections and 2) to develop Quantitative Technological Readiness Levels (Q-TRLs) for diagnostics to represent milestones and activities for the product development lifecycle from discovery through post-approval.
|